intestinal flora imbalance that is related to the development and worsening of the disease. b Objective: The purpose of this study was to evaluate the effects of probiotic yogurt on intestinal flora of patients with chronic liver disease. b Methods: A randomized controlled trial, pretestYposttest control group design, was used. Patients were randomized to an experimental group (41 patients) or a control group (40 patients) . Patients in the experimental group were given probiotic yogurt (one cup each time, three times per day for 14 days) containing Bacillus bifidus, Lactobacillus acidophilus, Lactobacillus bulgaricus, and Streptococcus thermophilus within 2 hours after meals. Levels of fecal flora, symptoms and signs, and laboratory examination indexes were collected. b Results: After intervention, the experimental group had a lower Escherichia coli count and reduced intestinal flora imbalance (p G .05). Comparison of the experimental and control groups after the intervention showed that the former had improved symptoms and signs, including significant improvement in debilitation, food intake, appetite, abdominal distension, and ascitic fluid (p G .05). b Conclusion: Probiotic yogurt reduces the levels of intestinal flora imbalance and has an additional therapeutic effect on patients with chronic liver disease. b Key Words: intestinal flora imbalance & probiotics & yogurt C hronic liver diseases, such as liver cirrhosis and chronic severe hepatitis, can lead to gastrointestinal congestion, microvilli damage, change in intestinal pH, overuse of antibiotics, and acute onset in pathogenesis. These factors may result in an intestinal flora imbalance that will worsen liver damage and increase the incidence of enterogenic infection, endotoxemia, and hepatic encephalopathy (Wu & Li, 2006) . To restore intestinal flora balance, microecological preparationsVmedicines containing probioticsVare used in clinical practice to supplement the beneficial bacteria and to prevent and treat the intestinal flora imbalance.
Generally, natural intestinal flora maintains a natural balance. However, diseases, mental stress, and drug treatment may result in flora imbalance (Serino, Luche, Chabo, Amar, & Burcelin, 2009 ). Because of abnormal hepatic functions, increased intestinal permeability, and microvilli damage, patients with chronic liver disease generally have some level of intestinal flora imbalance, as indicated by a decreased anaerobe count and increased aerobe count (Wu & Li, 2006) . The extent of intestinal flora imbalance is related to the degree of hepatic dysfunction rather than to the causes of liver cirrhosis.
The ChildYPugh classification is a means of assessing the severity of liver cirrhosis. The five indicators of patients (general condition, ascites, serum bilirubin, serum albumin concentration, and prothrombin time) were divided into three levels (denoted by 1, 2, and 3 points) and five index points summed (minimum is 5 points, and highest is 15 points). According to the sum of the number of the liver functional reserve, these are divided into A, B, and C, indicating the extent of three different liver damage levels (the higher the score, the worse the liver functional reserve). Patients with ChildYPugh stage C cirrhosis have a more obvious increase of enterococci and decrease of Bacillus bifidus than patients with ChildYPugh stage A (Zhao, Wang, Ly, & Xu, 2003) .
Moreover, patients with chronic liver disease and intestinal flora imbalance have an excess of Enterobacteriaceae, which may lead to an increase of enterogenic toxicants, such as ammonia, endotoxin, mercaptan, and benzodiazepine, and provide greater opportunity for Gram-negative bacilli penetration; if the liver is dysfunctional, then it cannot metabolize the toxicants fast enough and they will stagnate in the body. This will worsen hepatic dysfunction and promote the incidence of enterogenic infection, endotoxemia, and hepatic encephalopathy (Wu & Li, 2006) .
Changes in intestinal microecology takes place through endotoxin and Gram-negative bacilli, accelerating the development of chronic liver diseases. In recent years, microecological methods have been used to prevent and treat intestinal flora imbalance. Microecological preparations are used to restore intestinal flora balance in clinical practice, and studies have shown that they can reduce intestinal flora imbalance effectively, reduce plasma endotoxin level, and improve hepatic functions for patients with chronic liver disease (Loguercio et al., 2005; Lourens-Hattingh & Viljoen, 2001) . In China, common preparations include Medilac-Vita, Jinshuangqi (live combined Bifidobacterium lactobacillus and Streptococcus thermophilus tablet), Zhengchangsheng (Bacillus licheniformis capsule), and VSL#3. However, patients cannot use these drugs for a long period.
Yogurt is a carrier of probiotics; it is eaten widely as a healthy food, and yogurt can be eaten for any length of time. Probiotic yogurt is effective as an adjunctive treatment of lactose intolerance, ulcerative colitis, Helicobacter pylori infection, and diarrhea (Boudraa et al., 2001; Kato et al., 2004; Lourens-Hattingh & Viljoen, 2001; Myllyluoma et al., 2005) . For children in day care, long-term consumption of probiotic milk could reduce respiratory infections and severity (Hatakka et al., 2001) . It is also beneficial for healthy people (Chen, Wu, Lee, Huang, & Wu, 1999; Lourens-Hattingh & Viljoen, 2001) . However, no publication was found of probiotic yogurt used in the treatment of intestinal flora imbalance for patients with chronic liver disease.
The aims of this study were (a) to explore whether oral administration of probiotic yogurt can decrease symptoms and signs of patients with chronic liver disease and (b) to explore whether probiotic yogurt containing B. bifidus, Lactobacillus acidophilus, Lactobacillus bulgaricus, and S. thermophilus can reduce the incidence of intestinal flora imbalance for patients with chronic liver disease. The research hypotheses of the study were that, for patients with chronic liver disease, administration of probiotic yogurt (a) provides an additional treatment effect manifested by decreased symptoms and signs, (b) changes the intestinal flora count, and (c) reduces the incidence of intestinal flora imbalance when pretreatment values are compared with posttreatment values of the experimental group and when experimental and control group values are compared.
Methods

Design and Sample
A randomized controlled trial, pretestYposttest control group design was used. The study was conducted at Beijing YouAn Hospital, affiliated with Capital Medical University, from April 2007 to March 2008. The institutional review board of the university approved this study, and verbal informed consent was obtained from each subject.
Patients were included if they (a) conformed to the diagnostic criteria of liver cirrhosis or chronic severe hepatitis, (b) were aged 18 to 65 years, and (c) agreed to participate in the study. Patients were excluded if they (a) had hepatic encephalopathy, (b) had a history of other gastrointestinal diseases, (c) had taken antibiotics or a microecological preparation within 2 weeks, or (d) had diabetes. Eligibility was established, and 85 hospitalized patients with liver cirrhosis or chronic severe hepatitis were selected. All patients conformed to the Diagnostic Criteria of Chronic Severe Hepatitis and Liver Cirrhosis in Virus Hepatitis (CMA, Society of Infectious Disease and Parasitic Disease, and Society of Hepatopathy, 2001).
Patients were removed from the study if they (a) had received antibiotics or a microecological preparation during the intervention, (b) had less than 2 weeks of observation, or (c) did not take their yogurt on time.
The 85 hospitalized patients were allocated randomly to two groups, experimental (n = 44) and control (n = 41), using a random number table. Four subjects were lost to follow-up, and 81 subjectsV41 in the experimental group and 40 in the control groupVwere analyzed (Figure 1 ).
Intervention
Both groups of patients received the same treatment for liver protection and treatment of jaundice. Taking into account the patients' period of hospitalization, subjects in the experimental group received probiotic yogurt: one cup each time, three times per day, 100 g per cup, and 1 billion probiotics per 100 g within 2 hours after meals for 14 days. Probiotics contained in the yogurt were L. bulgaricus, L. acidophilus, B. bifidus, and S. thermophilus. The probiotic yogurt used was well known and made in China and was bought by study investigators in supermarkets and provided free to the subjects. The yogurt was taken generally 5 to 7 days after date of manufacture. Subjects in the control group had meals only and were not provided with the probiotic yogurt; if a patient in the control group consumed any type of probiotic yogurt during the study period, he or she was excluded from the data.
Observation Indexes
The data were collected by observation record sheets in five parts: (a) demographic dataVsex, age, occupation, marital status, medical diagnosis, hepatic function level, and duration of liver disease; (b) symptoms and signsVhypodynamia, appetite, food intake, abdominal distension, nausea and vomiting, ascites, times of defecation in previous 3 days, Probiotic Yogurt and Chronic Liver Disease 427 and characteristics of feces; (c) hepatic function indexesV prothrombin activity, glutamic-pyruvic transaminase, albumin, prealbumin, cholinesterase, total bilirubin, and cholesterol; (d) routine blood indexesVhemoglobin and red blood cell count; and (e) plasma endotoxinVexamined with the revised limulus test.
Hypodynamia was divided into four levels: no hypodynamia, mild (feel tired when doing intense activities, such as running), medium (feel tired when doing mild activities, but can take care of themselves), and severe (feel tired when in bed, cannot take care of themselves). Appetite was divided into four levels: Level 1, slightly diminished; Level 2, poor, but feeling hunger and desiring food; Level 3: very poor, with no feeling of hunger; and Level 4: anorexia, eating very little. Food intake was divided into four levels: Level 1, food intake decrease approximately 1/4; Level 2, food intake decrease approximately 1/2; Level 3, food intake decrease approximately 2/3; and Level 4, food intake decrease approximately 3/4. Abdominal distension was divided into four levels: no abdominal distension, mild (occasionally, can relieve themselves), medium (frequently, may still suffer), and severe (severe abdominal distension, unbearable, need medical treatment). Nausea and vomiting was divided into four levels: no nausea or vomiting, mild (feel nausea, but no vomiting, still could take in appropriate amount of food), moderate (feel nausea, vomiting, and eating little food), and severe (feel nausea, vomiting, not taking in food). Ascites was divided into four levels: no ascites, small amount (slight shifting dullness, or shifting dullness is negative but B-type ultrasonography shows ascites), medium amount (obvious shifting dullness), and large amount (obvious abdomen bulge and abdominal distension or tension).
Data for demographic data, symptoms, and signs were collected by self-report and medical review; for hepatic function indexes, routine blood indexes and plasma endotoxin were collected by medical review. All data were collected at two times: the day before intervention and the last day of study.
Microbiological Analysis of Feces
Two representative aerobes (enteric bacilli and enterococci) and three representative anaerobes (B. bifidus, lactobacilli, and bacteroid) in intestinal flora were chosen for study. Fresh feces (3Y5 g) were collected from each subject. Feces (0.1 g) from the middle of the sample was weighed and transferred to 0.9 ml sterile saline for dilution; the solution was homogenized, then diluted to serial dilutions: 10 j1 , 10 j2 , 10 j3 , I, 10 j9 . Ten dilutions were obtained, including the stock solution. A portion (0.01 ml) of each diluent was weighed and inoculated on an appropriate medium (Zhang, Liu, Zhang, & Chen, 2008) .
Criteria for Intestinal Flora Imbalance Level
Intestinal flora imbalance can be divided into three categories according to the flora imbalance classification and significance of the live flora count (Li, 2002; Xiong & Wu, 2005) . Flora imbalance I refers to potential flora imbalance. It can be detected only by a bacteria count examination: B. bifidus and bacteroid are decreased slightly and enteric bacilli and enterococci are increased slightly. There are no clear symptoms or only slight reactions like diarrhea. Flora imbalance II refers to limited flora imbalance. This generally results in chronic diseases, such as chronic enteritis, chronic pyelonephritis, and chronic stomatitis. The B. bifidus count decreases, and bacteroid is not always detected. The enteric bacilli count increases, whereas the enterococci count increases or remains unchanged. Flora imbalance III refers to intestinal dysbacteriosis. This flora imbalance is diffuse and is named microbial substitution or superinfection. Most original flora are inhibited, and only a few bacteria are dominant. Clinical symptoms are acute diarrhea and increased frequency of defecation, usually with mucous, watery, or bloody purulent feces. The count of B. bifidus and bacteroid decreases. The count of enteric bacilli and enterococci increases or remains unchanged.
Statistical Analysis
The Statistical Package for the Social Sciences for Windows (Version 10.0; SPSS Inc., Chicago, IL) was used for data analysis. A test of normality was performed for continuous data. If the data had a normal distribution, then a paired t test or an independent-samples t test was performed, and for data with a nonnormal distribution, a paired rank sum test or independent-samples rank sum test was performed. A paired # 2 test and a Column Â Row # 2 test were performed for nominal data. A paired rank sum test and an q independent-samples rank sum test were performed for ordinal data. Age, times of hospitalization, length of liver disease, international normalized ratio, prothrombin activity, cholinesterase, prealbumin, albumin, albumin to globulins ratio, serum cholesterase, red blood cell count, hemoglobin, aerobe, and anaerobe met a normal distribution. Data for glutamic-pyruvic transaminase, glutamic-oxaloacetic transaminase (GOT), aspartate aminotransferase/alanine aminotransferase, bilirubin total, and bilirubin direct had a nonnormal distribution.
Results
Demographic Data
Eighty-one people were included in the study (52 men, 64.2%; M T SD age = 48.62 T 11.11 years, range = 18Y65 years); 9 patients had severe hepatitis and 72 had liver cirrhosis. Of the 72 subjects with liver cirrhosis, 10 were in the compensation stage and 62 were in the decompensation stage; 28 of them were Level A in the ChildYPugh classification, 33 were Level B, and 11 were Level C; average duration of liver q Probiotic Yogurt and Chronic Liver Disease 429 disease was 10.94 T 9.68 years (range = 5Y40); and the number of times of admission was 2.48 T 1.62 times (range = 1Y10; Table 1 ).
Comparison of the Experimental and Control Groups Before the Intervention
Demographic data, symptoms and signs, laboratory examination indexes, intestinal flora, and flora imbalance level of the experimental and control groups were determined before the intervention. Both groups had similar demographic and clinical characteristics at that time when tested statistically (p 9 .05).
Intragroup Comparison Before and After Intervention
After intervention, the experimental group had reduced hypodynamia, improved appetite, increased food intake, reduced abdominal distension and ascites, and improved feces characteristics (p G .05), whereas in the control group only appetite showed significant improvement (p G .05). Thus, subjects in the experimental group had more significant improvement in symptoms and signs than the control group (Table 2) . After intervention, the experimental group had more prothrombin activity, less glutamic-pyruvic transaminase and GOT, and more serum cholesterol (p G .05); the control group had less transaminase and GOT, aspartate aminotransferase/ alanine aminotransferase, and bilirubin total (p G .05). Both groups had significantly improved hepatic functions after treatment for liver protection and jaundice (Table 3) .
After intervention, the experimental group's Escherichia coli count was reduced significantly (p G .05). There were significant differences in pre-and postintervention intestinal flora in the experimental group (p G .05; Table 4 ).
Comparison of the Experimental and Control Groups
After the Intervention After intervention, the symptoms of the experimental group were compared with those of the control group, and the experimental group had greater reductions in hypodynamia, abdominal distension, and ascites and greater improvement in appetite and food intake (p G .05) than the control group (Table 5) .
Intestinal flora and laboratory examination indexes of the experimental and control groups were compared also, but the differences were not statistically significant. Thus, the symptoms and the signs of subjects in the experimental group after a 2-week administration of probiotic yogurt were improved more significantly than those of the control group. 
Discussion
Subjects in the experimental group had significant improvements in clinical symptoms and signs. The major reason for recovery was the normal treatment of chronic liver disease and was demonstrated by improvement in biochemical indicatorsVfor example, a decrease of transaminase, bilirubin, and plasma endotoxin; increase of prothrombin activity, prealbumin, and albumin; and reduction of clinical symptoms and signs. Meanwhile, the probiotics in yogurt regulated intestinal flora in the ways described below, which could have affected patients' clinical symptoms and signs indirectly. First, B. bifidus and L. acidophilus in the yogurt directly increases the number of intestinal beneficial bacteria, and biological antagonism reduces the content of harmful bacteria and putrefying bacteria, and therefore intestinal flora balance was maintained. Second, the metabolic processes of B. bifidus and L. acidophilus lead to the production of organic acids such as formic acid, acetic acid, and lactic acid and also to the production of hydrogen peroxide and antibiotics. This increase in acidity and growth of antibiotics in the intestinal tract inhibits the reproduction of putrefying bacteria, weakens abnormal food fermentation and microorganism decomposition in the intestinal tract, and reduces the production of gases in the intestine. In addition, increased acidity in the gastrointestinal tract promotes gastric secretion, stimulates gastrointestinal motility, and improves gastrointestinal digestion. Third, B. bifidus can synthesize many kinds of folic acid and B vitamins, which provide nutrition for the human body; it can also decompose protein, sugar, and fat in food, thus promoting good digestion and absorption. Therefore, administration of probiotic yogurt has an adjuvant contribution to mitigation of symptoms like abdominal distension, hypody-namia, and diarrhea and can improve appetite and enhance digestion.
Effect of Probiotic Yogurt on Intestinal Flora
The experimental group had a decreased E. coli count and reduced intestinal flora imbalance after oral administration of probiotic yogurt. The yogurt used in the study contained four kinds of bacteria, L. bulgaricus, S. thermophilus, L. acidophilus, and B. bifidus. Of these, L. acidophilus and B. bifidus can withstand gastric acid and bile, so they can colonize in the intestinal tract and increase the number of beneficial flora directly. In addition, they are important components of the mucosal barrier of the intestine that resists the penetration of pathogenic bacteria and inhibits growth of conditioned pathogens like enteric bacilli and enterococci (Broekaert & Walker, 2006; Picard et al., 2005) .
L. bulgaricus and S. thermophilus cannot withstand gastric acid and bile, so they do not reach the intestinal tract alive. However, they do produce antibiotic substances that can kill or inhibit putrefying bacteria in the intestinal tract, increasing the percentage of beneficial flora indirectly. As a carrier of probiotics, yogurt can take beneficial bacteria to the intestinal tract and adjust the intestinal flora balance, so yogurt has an adjuvant effect similar to that of a microbiological preparation. Therefore, it can be used for a long period as a replacement for a microbiological preparation.
Limitations
Symptoms and signs of the experimental group improved very much after the intervention, but the intestinal flora count, the intestinal flora imbalance level, and the laboratory examination indexes did not show significant improvement. This might be related to the small sample size or short q Probiotic Yogurt and Chronic Liver Disease 431 intervention period (2 weeks). To further explore the effects of probiotic yogurt on intestinal flora imbalance for patients with chronic liver disease, a larger sample size or intervention over a longer period should be used in future studies.
Conclusion
Oral administration of probiotic yogurt can be used to supplement intestinal beneficial bacteria. It can reduce E. coli, effectively decrease clinical symptoms and signs, and help prevent and act as an additional treatment for intestinal flora imbalance for patients with chronic liver disease.Note. Level 1 is the best and Level 4 is the worst for appetite and food intake. *p G .05. **p G .01.
